Related references
Note: Only part of the references are listed.A signature of immune function genes associated with recurrence-free survival in breast cancer patients
Maria Libera Ascierto et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
Lei Bao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Conrad R. Cruz et al.
CLINICAL CANCER RESEARCH (2011)
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
Amberly Moreno-Bost et al.
CYTOTHERAPY (2011)
Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse
Maciej Kmieciak et al.
JOURNAL OF IMMUNOLOGY (2011)
Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure
Maciej Kmieciak et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect
Andrew McLarnon et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
Masanori Nojima et al.
CLINICAL CANCER RESEARCH (2009)
Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2009)
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-γ in promyelocytic cells
Andrea De Lerma Barbaro et al.
INTERNATIONAL IMMUNOLOGY (2008)
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
Atsushi Natsume et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Genome-wide analysis of cancer/testis gene expression
Oliver Hofmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma:: Immunotherapeutic implications
Ester Fonsatti et al.
CLINICAL CANCER RESEARCH (2007)
Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma
Chor-Sang Chim et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth
Hiro Tatetsu et al.
CANCER RESEARCH (2007)
Cancer/testis genes in multiple myeloma:: Expression patterns and prognosis value determined by microarray analysis
Maud Condomines et al.
JOURNAL OF IMMUNOLOGY (2007)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Cancer-testis antigens in haematological malignancies
Farouk Meklat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications
S Coral et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model
ZS Guo et al.
CANCER RESEARCH (2006)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport et al.
NATURE MEDICINE (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
AA Jungbluth et al.
BLOOD (2005)
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
F van Rhee et al.
BLOOD (2005)
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
R Bellucci et al.
BLOOD (2005)
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
DB Miklos et al.
BLOOD (2005)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
R Bellucci et al.
BLOOD (2004)
Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies
ZQ Wang et al.
BLOOD (2003)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
